Venetoclax
Acute Myeloid Leukemia
European Organisation for Research and Treatment of Cancer - EORTCSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 73/ 100
- Competitive Position
- 59/ 100
Competitive context
587 Active assets in the Acute Myeloid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gemtuzumab M.D. Anderson Cancer Center | Phase 4 | A |
Amsacrine University Hospital, Toulouse | Phase 4 | BBB |
Posaconazole AstraZeneca | Phase 4 | BBB |
(+)-Vincristine Janssen Research & Development, LLC | Phase 3 | BBB |
Aclacinomycin Chinese PLA General Hospital | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Venetoclax is also rated in:
chronic lymphocytic leukemia/small lymphocytic lymphomaActive
BB
Indicative · Phase 4
70 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →